-
The FDA has approved the first drug for the treatment of moderate-to-severe Alzheimers disease. Memantine, a noncompetitive inhibitor of the N-methyl-D-aspartate receptor, has been available outside of the United States since 1982.
-
Most postmenopausal women who suffer a fracture do not receive treatment for osteoporosis.
-
-
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
-
The objective of this monograph is to provide an overview of the scope of allergic disorders, and review the current understanding of the mechanism of the allergic response. Due to the extensive nature of the topic, we will limit our discussion to systemic reactions eliciting an IgE-mediated response. Further, the intimate relationship between organs involved will be reviewed, particularly the relationship between allergic rhinitis and asthma. Part I includes the current evaluation, including historical features, exposures, physical exam findings, and ancillary diagnostic options will be reviewed.
-
Update your knowledge on current issues in reproductive health at the annual Contraceptive Technology conference. The Washington, DC, session is scheduled for Feb. 29-March 3, with the San Francisco session set for March 24-27.
-
Searching for male-centered information to boost your facilitys services to men?
-
Your next patient is a young woman who has pressed for an appointment Monday morning after her boyfriends condom broke on Sunday night. Your formulary calls for use of progestin-only emergency contraception pills (ECPs). What is your next step?
-
New developments are arising on the vasectomy front, with researchers taking a look at the effectiveness of different methods of vas deferens occlusion and identifying chemical candidates to help speed up time to vasectomy success.